Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

New peptide fragments teach the gut to tolerate food

In little moments like when sipping coffee or licking an ice cream cone, it doesn't seem like your body is pulling off a biological miracle. But it is. That cookie is not you-yet when you put it in your mouth, your body is able to tolerate it and process it wi

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

In little moments like when sipping coffee or licking an ice cream cone, it doesn't seem like your body is pulling off a biological miracle. But it is. That cookie is not you-yet when you put it in your mouth, your body is able to tolerate it and process it without any detriment to your health in a process called oral tolerance. How does the human body make that decision between tolerance and rejection?

A study led by Stanford University scientists, including first and co-corresponding author Jamie Blum, PhD, who conducted the research at Stanford and recently joined the Salk Institute, and senior and co-corresponding author Elizabeth Sattely, PhD, who is an associate professor at Stanford, identifies new bits of food proteins that tell gut immune cells when to tolerate certain foods.

They found three of these protein segments, called epitopes, on each from soybean, corn, and wheat. These epitopes interact with specialized immune cells called regulatory T cells to inform that tolerance-or-rejection decision. The findings are an enormous step forward in understanding food tolerance, and may inform future immunotherapies for people with food allergies.

The study was published in Science Immunology on March 6, 2026, and was funded by federal research grants from the National Institutes of Health and National Science Foundation, as well as by private philanthropy.

As someone interested in foundational science, there's value in understanding a normal immune process along with pathology. Understanding how the immune system can normally see a protein as safe may lead to new therapies to promote tolerance in individuals with allergy." Jamie Blum, Study Co-Corresponding Author and Assistant Professor, NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute

How do food allergies work?

Since 6% of young children and 3% to 4% of adults experience food allergies, scientists have been hard at work figuring out exactly what elicits these allergic reactions to foods that should be safe. So far, their efforts have revealed specific proteins in top allergens, like peanut and egg, that cause adverse immune reactions. These proteins are recognized by antibodies, which then activate two of the immune system's fast-acting inflammatory cells, mast cells and basophils. If we know how and what the immune system reacts to during an allergy, shouldn't we know how and what the immune system reacts to during tolerance? Scientists have the "how" mostly covered. Already, there is a solid understanding that regulatory T cells are involved in tolerance. Prior research has revealed the anti-inflammatory and general immune-suppressive role that regulatory T cells play in tolerance, but "what" proteins prompt this non-reaction has remained unknown.

What proteins does the body tolerate?

The study began with a bowl of mouse chow. Rather than start piecewise, one food after another, the researchers screened regulatory T cells from mice given a normal diet. They looked for what the regulatory T cells were attaching to, then mapped them backward to specific parts of the chow. They found three proteins-more specifically, they found small, specific bits of those proteins called epitopes-that the regulatory T cells recognized. The epitopes were found in three different food proteins: one from corn, one from wheat, and one from soybean. Notably, all three epitopes are from seed proteins, suggesting that these highly abundant plant proteins are commonly recognized by the immune system's tolerance mechanisms. Furthermore, the most abundant T cells were those reactive to the corn epitope, which makes sense given that corn is not a common allergy. Soy, on the other hand, is one of the major allergies in humans, so the identification of a soybean epitope is especially exciting, notes Blum. Additionally, the mammalian receptor that interacts with the identified soybean epitope also interacts with sesame, helping explain cross-tolerance, or when a tolerance to one food infers a tolerance to another. With the new epitopes identified, the researchers had a few follow-up questions, like where do these regulatory T cells live? And how do they perform in an inflamed versus a healthy environment? They used mice and cell culture models to answer these questions, finding that the regulatory T cells are primarily located in the gut and their activities vary based on whether they are in an inflamed or healthy environment, either working to reduce inflammation or sustain an absence of inflammation.

Could we one day get rid of food allergies?

These seed epitopes are an exciting new addition to our understanding of oral tolerance. Scientists have already considered regulatory T cells as a promising immunotherapy route for people with severe food allergies. It may one day be possible to create regulatory T cells that are pre-programmed to tolerate certain foods and dampen immune responses to common allergens. "Diet is our most intimate interaction with our environment," says Blum. "Correctly recognizing foods as safe creates an anti-inflammatory environment to support nutrient acquisition and prevent allergy. Our research advances scientific understanding of the major dietary allergens, and points us toward future therapeutic interventions that could redirect allergic and autoimmune states." In the less-distant future, the researchers are excited to see their workflow for mapping proteins adapted to humans. The reagent they developed to track their proteins is now available for others to use, so they're hopeful that new insights into regulatory T cell-mediated oral tolerance are soon to come. Blum J. E., et al. (2026). Identification and characterization of dietary antigens in oral tolerance. Science Immunology. DOI: 10.1126/sciimmunol.aeb4684, https://www.science.org/doi/10.1126/sciimmunol.aeb4684.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What are BCAAs?

Food-derived proteins are broken down during digestion releasing amino acids which are then used by the body to create proteins required by bodily organs, tissues, and cells. The body can code for 20 different types of amino acids. However, some amino acids are considered to be essential whereby they cannot be synthesized in large enough quantities by the body. Therefore, they must be consumed as part of a balanced diet. Non-essential amino acids are produced by the body. There are nine types of essential amino acids: phenylalanine, histidine, threonine, isoleucine, leucine, tryptophan, lysine, valine, and methionine. Of the nine essential amino acids, leucine, valine, and isoleucine are referred to as branched-chain amino acids. Generally, all three BCAAs act as a substrate to produce protein and energy. Leucine plays an additional role as an intercellular signaling regulator for the mechanisms of protein production. Typically, BCAAs are found in foods rich in proteins such as eggs, fish, red meat, dairy and chicken as well as soy proteins, nuts, and lentils. Research has found that as the production of protein is continuous, there is a need to replace lost protein. This need for continued protein intake has increased the popularity of BCAA supplements. For example, the inclusion of BCAA supplements into the diets of bodybuilders, athletes, and gym-goers has increased due to their proposed muscle-building benefits and ability to enhance performance.

Source: www.news-medical.net ↗
02What are Critical Outcome Technologies’ plans for the future?

We plan to out license COTI-2 for clinical development so that we can continue the preclinical development of a number of other projects behind COTI-2. Our company is built around a computational platform for drug discovery and preclinical drug development. We intend to turn our attention to our acute leukemia program for which we also have patents issued and a growing body of positive preclinical data.

Source: www.news-medical.net ↗
03Why do so many of the compounds fail?

One of the main reasons why compounds fail is that they actually don't work in the patients they are tested in. We may have picked the wrong target since although we've actually created a molecule that, for example, inhibits the activity of the protein in the disease, it may actually turn out that over activity of that e protein isn't as important as we thought it was in that disease. The other reasons molecules fail now is primarily unexpected toxicity. You could take a molecule all the way through to phase 3 trials – the biggest trials in patients – and suddenly find that in your long-term, two-year carcinogenicity studies in animals, that you've got something that is quite cancer-provoking, so you have to stop development. Those are the two reasons: efficacy and toxicity. Somehow, we've got to find a way of trying to increase the chances of success or making the process less costly and leaner.

Source: www.news-medical.net ↗
04With graph neural networks, foundation models, and diffusion models transforming the field, what can we predict reliably today that was difficult a decade ago and are there still any blind spots?

One major example is protein structure. Methods such as AlphaFold and Boltz-2 have transformed how we generate 3D structural data. Accurate protein structure prediction has been a decades-old challenge, and while there is still work to do on underrepresented protein classes, these models have opened an extraordinary pathway. We have also seen progress in multi-output models. Just over a decade ago (circa 2013), toxicology and property prediction models often focused on one endpoint at a time. Now, multi-output models, especially from methods such as graph neural networks (GNNs) and other deep learning methods, can predict multiple endpoints simultaneously. This allows for transfer learning between related properties. That creates opportunities across ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction and toxicology. Another exciting area is machine learning potentials. Molecular simulations traditionally rely on fixed mathematical functions to describe molecular interactions, but neural potentials can now replace or augment those functions. They can, in many cases, provide highly accurate simulations and structures at lower computational cost than quantum chemistry. However, its not just down to model architectures. The biggest blind spot behind all of these advances remains careful data curation, annotation, and collection. Open databases for example ChEMBL, PubChem and Chemspider together with data initiatives such as OpenADEMT and OpenBind to name but a few are making notable progress here. We still see some data for example on formulation chemistry often receiving less attention. Its is not just about data scale, but quality that is critical here to. Accessible high quality data sets are the fuel of AI methods. Architecture matters, but high-quality, accessible and abundant data is also absolutely critical.

Source: www.news-medical.net ↗
05A peptide identified in a fungus found in northern European pine forests possesses as much power as penicillin as well as vancomycin, according to an international team of researchers.

Reporting in the October 13 issue of Nature, a team from Denmark-based biotech company Novozymes, and researchers from Georgetown University Medical Center and the David Geffen School of Medicine at UCLA, say they have isolated "plectasin," the first defensin ever found in fungi. The research was performed at Novozymes laboratories in Denmark. Defensins are peptides, miniature protein molecules that are produced by a wide range of animals to protect themselves against infection. Humans have defensins in their white blood cells and in their skin, for example, but it is believed that this new fungal defensin, plectasin, is more potent and targets certain bacteria more specifically. Indeed, when plectasin was tested in the laboratory and in animals, it proved to be highly effective against the bacteria Streptococcus pneumoniae, and Streptococcus pyogenes, including strains that are now resistant to conventional antibiotics. These bacteria are responsible for such diseases as meningitis, community-acquired pneumonia, strep throat, life-threatening sepsis, and flesh destroying skin infections. The discovery of plectasin has implications for the development of defensins as a treatment against many common, and deadly, infections, and may initiate a new era of antibiotic discovery and development, said study co-author Michael Zasloff, M.D., Ph.D., Professor in the Departments of Surgery and Pediatrics at Georgetown University Medical Center. Zasloff says that the field of antibiotic development has not changed much since 1929 when Alexander Fleming realized that the fungal "bread mold" Penicillium, which had landed by chance in a Petri dish produced a substance that eliminated colonies of staphylococcal bacteria. "Most antibiotics used by humans are produced by fungi and certain soil bacteria," he said. "Using our existing tools of discovery, we have failed to uncover any new classes of antibiotics from these sources over the past decade. However, by utilizing a new genetic approach that allowed the team to discover plectasin, we now know that a whole class of antibiotics has been overlooked." "This finding (plectasin), and the existence of about 200,000 additional species of fungi, opens up a vast universe to explore for novel peptide antibiotics," said co-author Robert Lehrer, M.D., Distinguished Professor of Medicine at the David Geffen School of Medicine at UCLA. Plectasin, if proven safe and effective in humans, could be on the market by 2012, said Lehrer. Zasloff and Lehrer are known internationally as experts in antimicrobial peptides - the class of antibiotics that plectasin falls within - and in this study they collaborated with Novozymes, a Danish biotech company that led the research. Zasloff and Lehrer are the only two scientists from U.S. universities on the team of 20 researchers who co-authored the research paper. All life forms have to defend themselves against microbial invaders - bacteria, fungi, viruses - and to do this, they produce antimicrobial defensin peptides. In humans, defensins are made by specific white blood cells and immune cells that later engulf foreign invaders, and by the skin and mucous membranes, in order to kill microbes before they invade protective barriers. Researchers believe that fungi have a similar system of defense, especially since these plant-like organisms live off rotting matter, said Zasloff. "They must compete with other organisms, like bacteria and viruses, which also want to consume the same meal. In addition, they need to defend themselves from being eaten by the microbes which surround them." But he said no one had been able to find defensins in fungi using traditional research techniques, which involved growing fungi in liquid cultures and then testing the culture to see if it contained any antibiotic molecule. The research team instead used the latest genetic science to search for the defensins they thought fungi must have. Selecting the Pseudoplectania nigrella species of fungus may have been serendipitous, Lehrer said, but the Novozymes team used state-of-the-art biotechnology to intercept ,and interpret its genetic messages and exhibited tremendous skill in producing plectasin efficiently, economically, and in large amounts." "I started working on antimicrobial peptides over three decades ago, said Lehrer, and my laboratory first described human defensins in 1985. So, the discovery of plectasin makes me feel like a grandfather." Further examination revealed that this defensin, plectasin, resembles defensins found in spiders, scorpions, dragonflies and mussels - thus suggesting that the defensins found in insects, molluscs and fungi arose from a common ancestral gene, the researchers say. Based on this information, the scientists now believe that defensins appeared in living things more than a billion years ago. The investigators then turned to the National Center for Antimicrobials and Infection Control, the Danish equivalent of the U.S. Centers for Disease Control, to test plectasin in the laboratory for antimicrobial activity against a broad spectrum of bacteria. It showed potent activity against several species of Gram-positive bacteria, and was especially active against S. pneumoniae (the leading cause of pneumonia), including all known clinical strains and those that are now resistant to conventional antibiotics. "That is important because increasing bacterial resistance to conventional antibiotics threatens the future of many antibiotics in current use," Zasloff said. "In mouse studies, plectasin showed extremely low toxicity, and was as effective as vancomycin and penicillin in curing the animals of experimental peritonitis (inflammation of the lining of the abdominal cavity, which can be deadly) and pneumonia caused by S. pneumoniae, the researchers report. "Although the precise mechanism by which plectasin exerts its antimicrobial activity is still under investigation, it may work by a mechanism that is very different from traditional antibiotics, Zasloff said. "As a group, defensins exhibit activity against many types of bacteria, fungi, protozoa, and even viruses. It is entirely possible that fungal defensins will be discovered that could be developed against all of these human pathogens," Zasloff added.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →